Back to Search
Start Over
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
- Source :
- Journal of Managed Care & Specialty Pharmacy. 27:1513-1525
- Publication Year :
- 2021
- Publisher :
- Academy of Managed Care Pharmacy, 2021.
-
Abstract
- BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA appr...
- Subjects :
- Oncology
medicine.medical_specialty
Cutaneous squamous cell carcinoma
business.industry
Cost-Benefit Analysis
Health Policy
Cell
Antibodies, Monoclonal
food and beverages
Pharmaceutical Science
Pharmacy
Cost-effectiveness analysis
Pembrolizumab
Antibodies, Monoclonal, Humanized
Progression-Free Survival
United States
Antineoplastic Agents, Immunological
medicine.anatomical_structure
Internal medicine
Carcinoma, Squamous Cell
medicine
Advanced disease
Humans
Surgical excision
business
Subjects
Details
- ISSN :
- 23761032 and 23760540
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Journal of Managed Care & Specialty Pharmacy
- Accession number :
- edsair.doi.dedup.....663ed31a85930fb57c9c0d37149a2463